首页> 外文期刊>Scientific reports. >A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy
【24h】

A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy

机译:高通量平台的比较分析,用于验证糖尿病性视网膜病中循环microRNA信号

获取原文
           

摘要

MicroRNAs are now increasingly recognized as biomarkers of disease progression. Several quantitative real-time PCR (qPCR) platforms have been developed to determine the relative levels of microRNAs in biological fluids. We systematically compared the detection of cellular and circulating microRNA using a standard 96-well platform, a high-content microfluidics platform and two ultra-high content platforms. We used extensive analytical tools to compute inter- and intra-run variability and concordance measured using fidelity scoring, coefficient of variation and cluster analysis. We carried out unprejudiced next generation sequencing to identify a microRNA signature for Diabetic Retinopathy (DR) and systematically assessed the validation of this signature on clinical samples using each of the above four qPCR platforms. The results indicate that sensitivity to measure low copy number microRNAs is inversely related to qPCR reaction volume and that the choice of platform for microRNA biomarker validation should be made based on the abundance of miRNAs of interest.
机译:现在,MicroRNA被越来越多地认为是疾病进展的生物标记。已经开发了几种定量实时PCR(qPCR)平台来确定生物液中microRNA的相对水平。我们系统地比较了使用标准96孔平台,高含量微流控平台和两个超高含量平台对细胞和循环微RNA的检测。我们使用了广泛的分析工具来计算使用保真度评分,变异系数和聚类分析测得的运行间和运行间变异性和一致性。我们进行了无偏见的下一代测序,以鉴定糖尿病性视网膜病变(DR)的microRNA标记,并使用上述四个qPCR平台中的每一个系统评估了该标记在临床样品上的有效性。结果表明,测量低拷贝数的microRNA的灵敏度与qPCR反应量成反比,并且应基于感兴趣的miRNA的丰度来选择microRNA生物标记物验证平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号